This is why it is essential to approve Amendment No 2 to Recital 4 which avoids the risks of the monopoly which would arise if companies which were the first to be authorised to place an additive on the market were to remain the only ones able to continue marketing it during the re-evaluation procedure.
Derfor er det vigtigt at acceptere ændringsforslag 2 til punkt 4, som gør det muligt at undgå risikoen for monopoldannelse, hvis de firmaer, der allerede har været de første, der fik tilladelse til at bringe et tilsætningsstof på markedet, var de eneste, der kunne udnytte det i løbet af nyvurderingstidsrummet.